| [October 12, 2017] |
 |
Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets - Research and Markets
The "Frontier
Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by
Immunomodulators and PD-1 Like Targets" drug pipelines has been
added to Research and Markets' offering.
The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class
Pipeline Dominated by Immunomodulators and PD-1 Like Targets"
is a comprehensive study of disease pathogenesis, diagnosis, prognosis
and the treatment options available.
Specifically, this report:
-
Visualize the composition of the cancer immunotherapies market in
terms of dominant molecule types and targets, highlighting what the
current unmet needs are and how they can be addressed.
-
Analyze the cancer immunotherapies pipeline and stratify by stage of
development, molecule type and molecular target.
-
Assess the therapeutic potential of first-in-class targets. Using a
proprietary molecular target matrix tailored directly towards cancer
immunotherapies, first-in-class products have been assessed and ranked
according to clinical potential.
-
Helps to identif commercial opportunities in the cancer
immunotherapies deals landscape by analyzing trends in licensing and
co-development deals, and producing a list of first-in-class therapies
with no prior involvement in licensing or co-development deals.
Scope
-
The 3,100 products in active development, of which 989 are
first-in-class and therefore act on completely novel targets, far
exceed the scope of the current market. How will pipeline innovation
affect the future cancer immunotherapies market?
-
There are 322 distinct first-in-class molecular targets currently
being studied. Which of these hold the greatest potential to improve
future disease treatment with regard to their molecular target?
-
Multiple types of cancer immunotherapies exist. Which of these are the
most promising, and how does the ratio of first-in-class targets to
first-in-class products differ by stage of development and molecular
target class?
-
A significant number of first-in-class products have been identified
with some prior involvement in deals. How do deal frequency and value
compare between target families and molecule types, and which
first-in-class programs have not yet been involved in a licensing or
co-development deal?
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 The Case for Innovation in the Oncology Market
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signaling Pathways, Disease-Causing Mutations and First-in-Class
Molecular Target (News - Alert) Integration
7 First-in-Class Target Assessment
8 Deals and Strategic Consolidations
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xw6gqd/frontier_pharma
View source version on businesswire.com: http://www.businesswire.com/news/home/20171012005831/en/
[ Back To TMCnet.com's Homepage ]
|
